Human papillomavirus vaccination: what is the best choice? A comparison of 16 strategies by means of a decisional model

Epidemiology and Infection

Volumn 137, Issue 6, 2009, Pages 794-802

  Gasparini, R ^a   Amicizia, D ^a   Manfredi, P ^b   Ansaldi, F ^a   Lucioni, C ^c   Gallelli, G ^a   Panatto, D ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Wolters Kluwer Health Italy Ltd   (Italy)

Author keywords

Decisional model; HPV; Vaccination policies

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DETERMINATION; ARTICLE; CHILD; FEMALE; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MASS IMMUNIZATION; SENSITIVITY ANALYSIS; VACCINATION; VIRUS INFECTION; WART VIRUS; AGE DISTRIBUTION; DECISION MAKING; DECISION TREE; DRUG ADMINISTRATION; ECONOMICS; IMMUNOLOGY; METHODOLOGY; THEORETICAL MODEL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; DECISION MAKING; DECISION TREES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH POLICY; HUMANS; MODELS, THEORETICAL; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 67649695196     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268808001441     Document Type: Article

References (27)

1. Bosch FX, et al. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 2002; 55: 244-265.
2. Dasbash EJ, Elbasha H, Insinua RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiologic Reviews 2006; 28: 88-100.
3. Elbasha EH, Dasbach EJ, Insigna RP. Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Disease 2007; 13: 28-41.
4. Beck JR, Pauker SG. The Markov process in medical prognosis. Medical Decision Making 1983; 3: 419-458.
5. Elbasha EH, Galvani AP. Vaccination against multiple HPV types. Mathematical Biosciences 2005; 197: 88-117.
6. Plummer M, et al. A 2-years prospective study of HPV persistence among women with Ascus or LSIL cytology. Journal of Infectious Diseases 2007; 195: 1582-1589.
7. ISTAT 14th Italian population census. 21 October 2001 (www.demoistat.it). Accessed 8 January 2008.
8. Winer RL, et al. Risk of female human papillomavirus acquisition associated with first male sex partner. Journal of Infectious Diseases 2008; 197: 279-282.
9. Winer RL, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. American Journal of Epidemiology 2003; 157: 218-226.
10. Brown DR, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. Journal of Infectious Diseases 2005; 191: 182-192.
11. Sharma R, Sharma CL. Quadrivalent human papillomavirus recombinant vaccine: The first vaccine for cervical cancers. Journal of Cancer Research and Therapeutics 2007; 3: 92-95.
12. Garnett GP, et al. Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006; 24 (Suppl. 3): 178-86.
13. Munoz N, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003; 348: 518-527.
14. Pagliusi SR, et al. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004; 23: 569-578.
15. Mao C, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. A randomized controlled trial. Obstretics and Gynecology 2006; 107: 18-27.
16. Paavonen J, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-2170.
17. Joura EA, et al. Efficacy of a quadrivalent prophylactic human against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693-1702.
18. Harper DM, et al. Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human Papillomavirus types 16 and 18: Follow-up from a randomised trial. Lancet 2006; 367: 1247-1255.
19. Villa LL, et al. High sustained efficacy of a prophylactic quadrivalent human Papillomavirus types 6/11/16/18 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer 2006; 95: 1459-1466.
20. Sewell EC, Jacobson SH, Weniger BG. 'Reverse engineering' a formulary selection algorithm to determine the economic value of pentavalent and hexavalent combination vaccines. Pediatric Infectious Disease Journal 2001; 20 (Suppl. 11): S45-S56.
21. Coudeville L, et al. Varicella vaccination in Italy: An economic evaluation of different scenarios. Pharmacoeconomics 2004; 22: 839-855.
22. Bosch FX, de Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Disease Markers 2007; 23: 213-227.
23. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: Unresolved issues. Nature Reviews Cancer 2007; 7 11-22.
24. Barnabas RV, et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling Analysis. PLOS Medicine 2006; 3: 624-632.
25. Markowitz LE, et al. Quadrivalent human papillomavirus vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 2007; 56: 1-24.
26. Saslow D, et al. American Cancer Society Guideline for human Papillomavirus (HPV). Vaccine use to prevent cervical cancer and its precursors. A Cancer Journal for Clinicians 2007; 57: 7-28.
27. Garland SM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine 2007; 356: 1928-1943.